查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1269446

充血性心臟衰竭治療藥市場(充血性心臟衰竭的類型:左心衰竭，右心衰竭，高功率心臟衰竭)-全球產業分析，規模，佔有率，成長，趨勢，預測，2023-2031年

Congestive Heart Failure Drugs Market (Type of Congestive Heart Failure: Left-sided Heart Failure, Right-sided Heart Failure, and High-output Heart Failure) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 162 Pages | 商品交期: 2-10個工作天內

價格

充血性心臟衰竭治療藥市場- 調查範圍:

TMR 的研究報告《全球充血性心臟衰竭治療藥市場》為了提供2023年～2031年預測期間上關於市場指標的寶貴知識和見解，不僅探討了過去的增長趨勢，還調查了當前的增長趨勢和機會。本報告以 2023 年為基準年，2031 年為預測年。提供2017年到2031年的全球充血性心臟衰竭治療藥市場收益。並刊載2023年2031年的全球充血性心臟衰竭治療藥市場年複合成長率。

本報告透過廣泛研究作成。初步研究中由分析師對主要意見領袖、行業領袖和輿論製造者進行訪談，並進行大部分研究工作。二次研究則參考主要公司的產品資料、年報、新聞稿和相關文件，來掌握充血性心臟衰竭治療藥市場。

該報告深入探討全球充血性心臟衰竭治療藥市場的競爭格局。鎖定全球充血性心臟衰竭治療藥市場活動的主要企業，並對每家公司進行了不同屬性的分析。介紹企業概要，財務狀況，最近的趨勢，SWOT等全球充血性心臟衰竭治療藥市場企業的屬性。

目錄

第1章 序文

  • 市場定義和規模
  • 市場區隔
  • 主要的調查目的
  • 調查亮點

第2章 前提條件與調查手法

第3章 摘要整理:全球市場

第4章 市場概要

  • 簡介
    • 市場區隔定義
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 全球市場的分析與預測，2017-2031年
    • 市場收益預測

第5章 主要洞察

  • 主要的產業活動
  • 開發平台分析
  • 心臟衰竭的疾病的盛行率概要

第6章 全球市場分析·預測:消化器官系統心臟衰竭類別

  • 簡介和定義
  • 主要調查結果/發展情形
  • 市場價值預測:消化性心臟衰竭類別，2017-2031年
    • 左側心臟衰竭
    • 右側心臟衰竭
    • 高功率型心臟衰竭
  • 市場魅力分析:消化器官系統心臟衰竭類別

第7章 全球市場分析·預測:各藥物類別

  • 簡介和定義
  • 主要調查結果·發展情形
  • 市場價值預測:各類藥物，2017-2031年
    • ACE抑制劑
    • 血管收縮素2受體阻斷劑
    • Beta Blockers
    • Mineralocorticoid Receptor Antagonists
    • Diuretics
    • Ivabradine
    • Sacubitril Valsartan
    • 其他(地高辛等)
  • 市場魅力分析:各藥物類別

第8章 全球市場分析·預測:各流通管道

  • 簡介和定義
  • 主要調查結果/發展情形
  • 市場價值預測:各流通管道，2017-2031年
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場魅力分析:各流通管道

第9章 全球市場分析·預測:各地區

  • 主要調查結果
  • 市場規模預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲地區
  • 市場魅力分析:各地區

第10章 北美市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場價值預測:消化器官系統心臟衰竭各類型，2017年～2031年
    • 左側心臟衰竭
    • 右側心臟衰竭(Right-sided Heart Failure
    • 高功率型心臟衰竭
  • 市場價值預測:各藥物類別，2017-2031年
    • ACE抑制劑
    • 血管收縮素2受體阻斷劑
    • β- 阻斷劑
    • 鹽皮質素受體拮抗劑
    • 利尿劑
    • Ivabradine
    • Sacubitril Valsartan
    • 其他(地高辛等)
  • 市場價值預測:各流通管道，2017-2031年
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場價值預測:各國，2017-2031年
    • 美國
    • 加拿大
  • 市場魅力分析
    • 消化性心臟衰竭類別
    • 各類藥物
    • 各銷售管道
    • 各國

第11章 歐洲市場分析·預測

  • 簡介
    • 主要的調查結果
  • 市場價值預測:消化器官系統心臟衰竭各類型，2017年～2031年
    • 左側心臟衰竭
    • 右側心臟衰竭
    • 高功率型心臟衰竭
  • 市場價值預測:各藥物類別，2017-2031年
    • ACE抑制劑
    • 血管收縮素2受體阻斷劑
    • β- 阻斷劑
    • 鹽皮質素受體拮抗劑
    • 利尿劑
    • Ivabradine
    • Sacubitril Valsartan
    • 其他(地高辛等)
  • 市場價值預測:各流通管道，2017-2031年
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場價值預測:國家·小各地區，2017-2031年
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲
  • 市場魅力分析
    • 消化性心臟衰竭類別
    • 各藥物類別
    • 各銷售管道
    • 各國/輔助region

第12章 亞太地區的市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場價值預測:消化器官系統心臟衰竭類別，2017年～2031年
    • 左側心臟衰竭
    • 右側心臟衰竭
    • 高功率型心臟衰竭
  • 市場價值預測:各藥物類別，2017-2031年
    • ACE抑制劑
    • 血管收縮素2受體阻斷劑
    • β- 阻斷劑
    • 鹽皮質素受體拮抗劑
    • 利尿劑
    • Ivabradine
    • Sacubitril Valsartan
    • 其他(地高辛等)
  • 市場價值預測:各流通管道，2017-2031年
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場價值預測:國家·小各地區，2017-2031年
    • 中國
    • 日本
    • 印度
    • 澳洲·紐西蘭
    • 其他亞太地區
  • 市場魅力分析
    • 消化性心臟衰竭類別
    • 各藥物類別
    • 各銷售管道
    • 各國/輔助region

第13章 南美的市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場價值預測:消化器官系統心臟衰竭類別，2017年～2031年
    • 左側心臟衰竭
    • 右側心臟衰竭
    • 高功率型心臟衰竭
  • 市場價值預測:各藥物類別，2017-2031年
    • ACE抑制劑
    • 血管收縮素2受體阻斷劑
    • β- 阻斷劑
    • 鹽皮質素受體拮抗劑
    • 利尿劑
    • Ivabradine
    • Sacubitril Valsartan
    • 其他(地高辛等)
  • 市場價值預測:各流通管道，2017-2031年
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場價值預測:各國/輔助各地區，2017-2031年
    • 巴西
    • 墨西哥
    • 其他南美國家地區
  • 市場魅力分析
    • 消化器官系統心臟衰竭類別
    • 各藥物類別
    • 各銷售管道
    • 各國/輔助region

第14章 中東·非洲市場分析·預測

  • 簡介
    • 主要調查結果
  • 市場價值預測:消化器官系統心臟衰竭類別，2017年～2031年
    • 左側心臟衰竭
    • 右側心臟衰竭(Right-sided Heart Failure
    • 高功率型心臟衰竭
  • 市場價值預測:各藥物類別，2017-2031年
    • ACE抑制劑
    • 血管收縮素2受體阻斷劑
    • β- 阻斷劑
    • 鹽皮質素受體拮抗劑
    • 利尿劑
    • Ivabradine
    • Sacubitril Valsartan
    • 其他(地高辛等)
  • 市場價值預測:各流通管道，2017-2031年
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場價值預測:國家/小各地區，2017-2031年
    • GCC各國
    • 南非
    • 其他中東·非洲
  • 市場魅力分析
    • 消化性心臟衰竭類別
    • 各藥物類別
    • 各銷售管道
    • 各國/輔助region

第15章 競爭情形

  • 市場競爭者-競爭矩陣(企業各層級，不同企業規模)
  • 市場佔有率分析:各企業, 2021年
  • 企業簡介
    • Bayer AG
    • Novartis AG
    • Merck & Co., Inc.
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Amgen, Inc.
    • Boehringer Ingelheim International GmbH
    • Pfizer, Inc.
    • Johnson & Johnson Services, Inc.
    • Eli Lilly and Company
Product Code: TMRGL85514

Congestive Heart Failure Drugs Market - Scope of Report:

TMR's report on the global congestive heart failure drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global congestive heart failure drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global congestive heart failure drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the congestive heart failure drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global congestive heart failure drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global congestive heart failure drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global congestive heart failure drugs market.

The report delves into the competitive landscape of the global congestive heart failure drugs market. Key players operating in the global congestive heart failure drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global congestive heart failure drugs market profiled in this report.

Key Questions Answered in Global Congestive Heart Failure Drugs Market Report:

  • What is the sales/revenue generated by congestive heart failure drugs across all regions during the forecast period?
  • What are the opportunities in the global congestive heart failure drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Congestive Heart Failure Drugs Market - Research Objectives and Research Approach:

The comprehensive report on the global congestive heart failure drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global congestive heart failure drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global congestive heart failure drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Congestive Heart Failure Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Congestive Heart Failure Drugs Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Key Industry Events
  • 5.2. Pipeline Analysis
  • 5.3. Heart Failure Diseases Prevalence: Overview

6. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Type of Digestive Heart Failure

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Type of Digestive Heart Failure, 2017-2031
    • 6.3.1. Left-sided Heart Failure
    • 6.3.2. Right-sided Heart Failure
    • 6.3.3. High-output Heart Failure
  • 6.4. Market Attractiveness Analysis, by Type of Digestive Heart Failure

7. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Drug Class

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Drug Class, 2017-2031
    • 7.3.1. ACE Inhibitors
    • 7.3.2. Angiotensin-2 Receptor Blockers
    • 7.3.3. Beta Blockers
    • 7.3.4. Mineralocorticoid Receptor Antagonists
    • 7.3.5. Diuretics
    • 7.3.6. Ivabradine
    • 7.3.7. Sacubitril Valsartan
    • 7.3.8. Others (digoxin etc.)
  • 7.4. Market Attractiveness Analysis, by Drug Class

8. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospitals Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Congestive Heart Failure Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017-2031
    • 10.2.1. Left-sided Heart Failure
    • 10.2.2. Right-sided Heart Failure
    • 10.2.3. High-output Heart Failure
  • 10.3. Market Value Forecast, by Drug Class, 2017-2031
    • 10.3.1. ACE Inhibitors
    • 10.3.2. Angiotensin-2 Receptor Blockers
    • 10.3.3. Beta Blockers
    • 10.3.4. Mineralocorticoid Receptor Antagonists
    • 10.3.5. Diuretics
    • 10.3.6. Ivabradine
    • 10.3.7. Sacubitril Valsartan
    • 10.3.8. Others (digoxin etc.)
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospitals Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Type of Digestive Heart Failure
    • 10.6.2. By Drug Class
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Congestive Heart Failure Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017-2031
    • 11.2.1. Left-sided Heart Failure
    • 11.2.2. Right-sided Heart Failure
    • 11.2.3. High-output Heart Failure
  • 11.3. Market Value  Forecast, by Drug Class, 2017-2031
    • 11.3.1. ACE Inhibitors
    • 11.3.2. Angiotensin-2 Receptor Blockers
    • 11.3.3. Beta Blockers
    • 11.3.4. Mineralocorticoid Receptor Antagonists
    • 11.3.5. Diuretics
    • 11.3.6. Ivabradine
    • 11.3.7. Sacubitril Valsartan
    • 11.3.8. Others (digoxin etc.)
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospitals Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Type of Digestive Heart Failure
    • 11.6.2. By Drug Class
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Congestive Heart Failure Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017-2031
    • 12.2.1. Left-sided Heart Failure
    • 12.2.2. Right-sided Heart Failure
    • 12.2.3. High-output Heart Failure
  • 12.3. Market Value  Forecast, by Drug Class, 2017-2031
    • 12.3.1. ACE Inhibitors
    • 12.3.2. Angiotensin-2 Receptor Blockers
    • 12.3.3. Beta Blockers
    • 12.3.4. Mineralocorticoid Receptor Antagonists
    • 12.3.5. Diuretics
    • 12.3.6. Ivabradine
    • 12.3.7. Sacubitril Valsartan
    • 12.3.8. Others (digoxin etc.)
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospitals Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Type of Digestive Heart Failure
    • 12.6.2. By Drug Class
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Congestive Heart Failure Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017-2031
    • 13.2.1. Left-sided Heart Failure
    • 13.2.2. Right-sided Heart Failure
    • 13.2.3. High-output Heart Failure
  • 13.3. Market Value Forecast, by Drug Class, 2017-2031
    • 13.3.1. ACE Inhibitors
    • 13.3.2. Angiotensin-2 Receptor Blockers
    • 13.3.3. Beta Blockers
    • 13.3.4. Mineralocorticoid Receptor Antagonists
    • 13.3.5. Diuretics
    • 13.3.6. Ivabradine
    • 13.3.7. Sacubitril Valsartan
    • 13.3.8. Others (digoxin etc.)
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospitals Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Type of Digestive Heart Failure
    • 13.6.2. By Drug Class
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Congestive Heart Failure Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017-2031
    • 14.2.1. Left-sided Heart Failure
    • 14.2.2. Right-sided Heart Failure
    • 14.2.3. High-output Heart Failure
  • 14.3. Market Value  Forecast, by Drug Class, 2017-2031
    • 14.3.1. ACE Inhibitors
    • 14.3.2. Angiotensin-2 Receptor Blockers
    • 14.3.3. Beta Blockers
    • 14.3.4. Mineralocorticoid Receptor Antagonists
    • 14.3.5. Diuretics
    • 14.3.6. Ivabradine
    • 14.3.7. Sacubitril Valsartan
    • 14.3.8. Others (digoxin etc.)
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospitals Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Type of Digestive Heart Failure
    • 14.6.2. By Drug Class
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Bayer AG
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Novartis AG
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Merck & Co., Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. AstraZeneca
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Bristol-Myers Squibb Company
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Amgen, Inc.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. Boehringer Ingelheim International GmbH
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. Pfizer, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. Johnson & Johnson Services, Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. Eli Lilly and Company
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Business Strategies
      • 15.3.10.5. Recent Developments

List of Tables

  • Table 01: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017-2031
  • Table 02: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 03: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017-2031
  • Table 07: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 08: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017-2031
  • Table 11: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 12: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017-2031
  • Table 15: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 16: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017-2031
  • Table 19: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 20: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017-2031
  • Table 23: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 24: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Congestive Heart Failure Drugs Market Value Share, by Type of Congestive Heart Failure, 2022
  • Figure 03: Global Congestive Heart Failure Drugs Market Value Share, by Drug Class, 2022
  • Figure 04: Global Congestive Heart Failure Drugs Market Value Share, by Distribution Channel, 2022
  • Figure 05: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
  • Figure 06: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023-2031
  • Figure 07: Global Congestive Heart Failure Drugs Market Value (US$ Mn), by Left-sided Heart Failure, 2017-2031
  • Figure 08: Global Congestive Heart Failure Drugs Market Value (US$ Mn), by Right-sided Heart Failure, 2017-2031
  • Figure 09: Global Congestive Heart Failure Drugs Market Value (US$ Mn), by High-output Heart Failure, 2017-2031
  • Figure 10: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
  • Figure 11: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023-2031
  • Figure 12: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by ACE Inhibitors, 2017-2031
  • Figure 13: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Angiotensin-2 Receptor Blockers (ARBs or AIIRAs), 2017-2031
  • Figure 14: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Beta Blockers, 2017-2031
  • Figure 15: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Mineralocorticoid Receptor Antagonists, 2017-2031
  • Figure 16: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Diuretics, 2017-2031
  • Figure 17: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Ivabradine, 2017-2031
  • Figure 18: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Sacubitril Valsartan, 2017-2031
  • Figure 19: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by others (digoxin etc.), 2017-2031
  • Figure 20: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 21: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 22: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Hospitals Pharmacies, 2017-2031
  • Figure 23: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 24: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 25: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 26: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 27: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 28: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 29: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country, 2023-2031 
  • Figure 30: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
  • Figure 31: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023-2031
  • Figure 32: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
  • Figure 33: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023-2031
  • Figure 34: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 35: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 36: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 38: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 39: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
  • Figure 40: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023-2031
  • Figure 41: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
  • Figure 42: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023-2031
  • Figure 43: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 44: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 45: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 46: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 47: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 48: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
  • Figure 49: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023-2031
  • Figure 50: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
  • Figure 51: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023-2031
  • Figure 52: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 53: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 54: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 55: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 56: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 57: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
  • Figure 58: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023-2031
  • Figure 59: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
  • Figure 60: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023-2031
  • Figure 61: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 62: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 63: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 64: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 65: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 66: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
  • Figure 67: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023-2031
  • Figure 68: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
  • Figure 69: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023-2031
  • Figure 70: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 71: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 72: Company Share Analysis, 2022